股票价格目标
Search documents
Wall Street Analysts See a 126.21% Upside in Immuneering (IMRX): Can the Stock Really Move This High?
ZACKS· 2025-11-26 15:56
Core Viewpoint - Immuneering Corporation (IMRX) has seen a 14.6% increase in share price over the past four weeks, closing at $7.44, with analysts suggesting a potential upside of 126.2% based on a mean price target of $16.83 [1][11]. Price Targets and Analyst Consensus - The average price target for IMRX is based on six short-term estimates, ranging from a low of $11.00 to a high of $30.00, with a standard deviation of $7.19, indicating variability in analyst predictions [2]. - The lowest estimate suggests a 47.9% increase from the current price, while the highest estimate indicates a potential upside of 303.2% [2]. - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price movement [9]. Earnings Estimates and Analyst Optimism - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases [4][11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 13.4%, with three estimates moving higher and no negative revisions [12]. - IMRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]. Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8].
Wall Street Analysts Think PRA Group (PRAA) Could Surge 41.95%: Read This Before Placing a Bet
ZACKS· 2025-11-26 15:56
Core Viewpoint - PRA Group (PRAA) has shown a 9% gain over the past four weeks, with a mean price target of $22.67 indicating a potential upside of 42% from the current price of $15.97 [1] Price Targets and Analyst Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $4.16, where the lowest estimate is $18.00 (12.7% increase) and the highest is $26.00 (62.8% increase) [2] - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has increased by 10.3% over the past month, with two estimates going higher and no negative revisions [12] - PRAA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' price targets can often be overly optimistic due to business incentives [3][8] - While price targets should not be ignored, they should be approached with skepticism, as they may not accurately predict stock price movements [10]
Best Buy Co., Inc. (NYSE:BBY) Financial Overview and Market Performance
Financial Modeling Prep· 2025-11-26 00:04
Core Insights - Best Buy Co., Inc. is a leading retailer in consumer electronics and appliances, facing competition from major players like Amazon and Walmart [1] - Barclays has set a price target of $81 for Best Buy, suggesting a potential increase of 1.73% from the current trading price of $79.62 [1][5] - The stock price of Best Buy has recently increased by 5.21%, reflecting active investor interest and market volatility [3][5] Financial Performance - Best Buy held its Q3 2026 earnings call, attended by key executives and analysts from major financial institutions, providing insights into the company's financial performance and strategic plans [2] - The current stock price of Best Buy is $79.56, with fluctuations between $75.02 and $80.53 during the trading day [3] - Over the past year, Best Buy's stock has experienced a high of $91.72 and a low of $54.99, indicating significant market volatility [3] Market Position - Best Buy's market capitalization is approximately $16.72 billion, highlighting its substantial presence in the retail sector [4] - The trading volume for Best Buy today is 4,986,918 shares, reflecting strong investor interest following the recent earnings call and updated price target [4]
Wall Street Analysts See a 27.67% Upside in OR Royalties (OR): Can the Stock Really Move This High?
ZACKS· 2025-11-25 15:56
Core Viewpoint - OR Royalties (OR) shares have increased by 6.2% in the last four weeks, closing at $33.65, with a potential upside indicated by Wall Street analysts' mean price target of $42.96, suggesting a 27.7% increase [1] Price Targets and Analyst Estimates - The mean estimate consists of 11 short-term price targets with a standard deviation of $7.02, where the lowest estimate is $35.00 (4% increase) and the highest is $61.92 (84% increase) [2] - A low standard deviation indicates a strong agreement among analysts regarding the stock's price movement [2][9] Analyst Optimism and Earnings Estimates - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11] - Over the past 30 days, the Zacks Consensus Estimate for the current year has risen by 3.8%, with four estimates moving higher and no negative revisions [12] Zacks Rank and Investment Potential - OR holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Conclusion on Price Movement - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for potential price movements [14]
Does Popular (BPOP) Have the Potential to Rally 26.8% as Wall Street Analysts Expect?
ZACKS· 2025-11-25 15:56
Core Viewpoint - Shares of Popular (BPOP) have shown a modest gain of 0.3% over the past four weeks, closing at $112.86, with analysts suggesting a potential upside of 26.8% based on a mean price target of $143.11 [1] Price Targets - The average price target consists of nine estimates ranging from a low of $127.00 to a high of $160.00, with a standard deviation of $10.72, indicating a potential increase of 12.5% to 41.8% from the current price [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Analyst Sentiment - Analysts have shown increasing optimism about BPOP's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, one estimate has increased while there have been no negative revisions, leading to a 1.8% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank - BPOP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside in the near term [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of the extent of potential gains, it does provide a useful guide for the direction of price movement [14]
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet
ZACKS· 2025-11-25 15:56
Shares of Bright Minds Biosciences Inc. (DRUG) have gained 2.9% over the past four weeks to close the last trading session at $60.47, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $82.4 indicates a potential upside of 36.3%.The average comprises five short-term price targets ranging from a low of $72.00 to a high of $93.00, with a standard deviation of $7.64. While the lowest ...
Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's What You Should Know
ZACKS· 2025-11-25 15:56
Shares of Altimmune, Inc. (ALT) have gained 23.2% over the past four weeks to close the last trading session at $5.1, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $17.88 indicates a potential upside of 250.6%.The mean estimate comprises eight short-term price targets with a standard deviation of $8.81. While the lowest estimate of $1.00 indicates a 80.4% decline from the curr ...
Can Great Lakes Dredge & Dock (GLDD) Climb 32.12% to Reach the Level Wall Street Analysts Expect?
ZACKS· 2025-11-24 15:56
Core Viewpoint - Great Lakes Dredge & Dock (GLDD) shows potential for significant upside, with a mean price target of $15.67 indicating a 32.1% increase from the current price of $11.86 [1] Price Targets and Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $1.53, suggesting variability among analysts [2] - The lowest estimate of $14.00 indicates an 18% increase, while the highest target of $17.00 suggests a 43.3% increase [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Analyst Sentiment and Earnings Estimates - Analysts exhibit growing optimism about GLDD's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11] - The Zacks Consensus Estimate for the current year has risen by 7.9% over the past month, with two estimates increasing and no negative revisions [12] - GLDD holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely predict actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]
Wall Street Analysts Believe LiveRamp (RAMP) Could Rally 46.42%: Here's is How to Trade
ZACKS· 2025-11-24 15:56
Core Viewpoint - LiveRamp (RAMP) shares have seen a 1% increase over the past four weeks, closing at $28.78, with a potential upside of 46.4% based on Wall Street analysts' mean price target of $42.14 [1][11]. Price Targets - The average price target consists of seven estimates ranging from a low of $33.00 to a high of $53.00, with a standard deviation of $7.8, indicating variability among analysts [2]. - The lowest estimate suggests a 14.7% increase from the current price, while the highest indicates an 84.2% upside [2]. Analyst Sentiment - There is strong agreement among analysts regarding RAMP's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11]. - The Zacks Consensus Estimate for the current year has increased by 3.3%, with one estimate moving higher in the last 30 days and no negative revisions [12]. Zacks Rank - RAMP holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside [13]. Caution on Price Targets - While price targets are a common metric for investors, relying solely on them can be misleading, as analysts may set overly optimistic targets due to business incentives [3][8][10].
Wall Street Analysts Believe MediaAlpha (MAX) Could Rally 34.32%: Here's is How to Trade
ZACKS· 2025-11-24 15:56
Core Viewpoint - MediaAlpha, Inc. (MAX) shows potential for significant upside, with a mean price target of $15.93 indicating a 34.3% increase from its current price of $11.86 [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $2.39, suggesting variability in analyst predictions [2] - The lowest estimate is $13.00, indicating a 9.6% increase, while the highest estimate is $19.00, suggesting a 60.2% increase [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts are optimistic about MAX's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - Over the last 30 days, two estimates have increased, leading to a 5.6% rise in the Zacks Consensus Estimate for the current year [12] - MAX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, and reliance solely on them may not yield favorable returns [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]